National Institute of Health and Care Excellence Recommends New CIU Drug
Chronic spontaneous urticaria (CSU) – called chronic idiopathic urticaria (CIU) in the U.S. – is a potentially disabling skin condition that, according to the World Allergy Organization, may affect as much as two percent of the U.S. population. This chronic skin disorder can cause severe itch, hives, and deep tissue swelling.
The traditional treatment with H1-antihistamines and leukotriene receptor antagonists (LTRAs) has been in place for several decades. But some patients do not respond to this treatment protocol.
The National Institute of Health and Care Excellence (NICE) in the UK recommended Xolair (omalizumab) as add-on treatment of patients who do not respond to regular treatment. The FDA approved the drug for treatment of CIU in patients who do not respond to regular treatment in 2014.
Clinical trials involving over 1,000 patients who showed no improvement with antihistamines found that omalizumab 300mg improved itch and hives, reports drug manufacturer Novartis. Compared to placebo, omalizumab completely cleared symptoms in many cases.
Finding relief from CIU is a critical matter for those suffering from the disease. Aside from the physical discomfort, the emotional impact can be significant. Flare-ups may cause patients to miss work or school, for example. Some suffer from anxiety and depression related to the condition.
CIU is a type of disabling condition that can result in both physical and mental impairment. It may have a significant impact on a patient’s quality of life and can often impair patients from working and earning a substantial income. If you or a loved one is severely afflicted with this condition or another chronic skin disorder you may be eligible for Social Security disability benefits. Contact the Disability Help Group today for assistance and support for your claim. Call today – 1-(800)-800-3332.